Intercept Pharma (ICPT) Misses Q4 EPS Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. CRWD
3. PLTR
4. REGN
5. LITE
6. ABBV
7. MRVL
8. CL
9. LYB
10. TFII

Go back to Intercept Pharma (ICPT) Misses Q4 EPS Views

Wedbush Cuts PT on Intercept Pharma (ICPT) to $423, Remains Bullish

February 24, 2016 8:17 AM EST

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharma (NASDAQ: ICPT) and thinks there will be a buying opportunity ahead of the release of AdComm briefing documents on April 7th. Acquisition value drops to $423 from $493 as expectations for the NASH launch are pushed to late19 from H1:18.

Intercept reported Q4 / FY revenues of $0.45MM / $2.78MM on GAAP EPS of $(3.62) / $(9.56) vs. consensus revenues est. of... More